Stock AQP AQUAPORIN A/S
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Aquaporin A/S

Equities

AQP

DK0061555109

Delayed Nasdaq Copenhagen
Other stock markets
 10:20:24 2024-04-24 am EDT 		5-day change 1st Jan Change
15 DKK 0.00% Intraday chart for Aquaporin A/S 0.00% -67.39%
Apr. 05 Transcript : Aquaporin A/S, 2023 Earnings Call, Apr 05, 2024
Apr. 05 Aquaporin A/S Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Aquaporin A/S Reports Earnings Results for the Full Year Ended December 31, 2023
Aquaporin A/S Provides Earnings Guidance for the Year 2024
London Stocks Retreat Ahead of Final UK GDP Data for Q4 2023
AstraZeneca Says Ultomiris Gets US FDA Approval to Treat Neuromyelitis Optica Spectrum Disorder
AstraZeneca Bags US FDA Clearance for Rare Autoimmune Disease Treatment Ultomiris
AstraZeneca Receives US Approval for Neuromyelitis Optica Spectrum Disorder Treatment
Aquaporin Announces Changes in Executive Management Team
Aquaporin A/S Provides Earnings Guidance for the Financial Year 2024
Aquaporin A/S Maintains Earnings Guidance for the Full Year 2023
AstraZeneca's Soliris Approved in China for Treatment of Neuromyelitis Optica Spectrum Disorder
AstraZeneca drug Solaris approved in China as NMOSD treatment
AstraZeneca's Rare Inflammatory Disease Drug for Adults Wins First-in-Class Nod in China
AstraZeneca working with FDA on Ultomiris risk evaluation changes
Aquaporin A/S Reaffirms Earnings Guidance for the Year 2023
Aquaporin A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
AstraZeneca's Ultomiris wins another approval in Japan
AstraZeneca Wins First-in-Class Nod for Rare Inflammatory Disease Drug Ultomiris in Japan
Aquaporin A/S Provides Earnings Guidance of the Full Year 2023
AstraZeneca's Rare Inflammatory Disease Drug Wins First-in-Class EU Approval
AstraZeneca's ultomiris recommended for EU approval
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AQP Stock
  4. News Aquaporin A/S
  5. Other languages